Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression

Cancer Biology and Therapy

Volumn 11, Issue 6, 2011, Pages 581-583

  Mosca, Paul J ^a   Robertson, Gavin P ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Calreticulin; Dendritic cell; Immunity; Melanoma; Phagocytosis; T cell

Indexed keywords

CALRETICULIN; INTERLEUKIN 2; IPILIMUMAB;

ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; DNA MODIFICATION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MELANOMA CELL; NONHUMAN; NOTE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; APOPTOSIS; CALRETICULIN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; PHAGOCYTOSIS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 79952763631     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.6.14697     Document Type: Note

References (13)

1. American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society 2010.
2. Korn EL, Liu PY, Lee SJ, Chapman JAW, Niedzwiecki D, Suman V, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26:527-34. (Pubitemid 351264344)
3. Agostino NM, Ali A, Nair SG, Mosca PJ. Current immunotherapeutic strategies in malignant melanoma. Surg Oncol Clin N Am 2007; 16:945-73. (Pubitemid 350101276)
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
5. Krummel MF, Davis MM. Dynamics of the immunological synapse: ?nding, establishing and solidifying a connection. Curr Opin Immunol 2002; 14:66-74. (Pubitemid 34085108)
6. Jansson A, Barnes E, Klenerman P, Harlen M, Sorensen P, Davis SJ, et al. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol 2005; 175:1575-85. (Pubitemid 41023059)
7. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010; 125:3-23.
8. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721-8. (Pubitemid 40977140)
9. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999; 59:3329-32. (Pubitemid 29334486)
10. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, et al. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res 2007; 67:7941-4.
11. Gelebart P, Opas M, Michalak M. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 2005; 37:260-6. (Pubitemid 39330186)
12. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123:321-34. (Pubitemid 41457220)
13. Qin Y, Han Y, Cao C, Ren, Y Li C, Wang Y. Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice. Cancer Biol Ther 2011; 11:574-80.